cSCC免疫治疗！默沙东Keytruda新适应症获美国FDA批准！
医普小新
发布时间：2020-06-30 14:52
43次浏览
关键词：
原文出处：
FDA
app
roves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
